- Abbokinase injection
- Abbokinase abbokinase side effects
- Abbokinase side effects
- Abbokinase dosage
- Abbokinase adult dose
- Abbokinase drug
Uses For Abbokinase
Urokinase injection is used to dissolve blood clots that have formed in the lungs (pulmonary embolism).
This medicine was available only with your doctor's prescription.
This medicine is not available in the United States as of October 2010.
Abbokinase Side Effects
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur:More common
- Bleeding gums
- coughing up blood
- difficulty with breathing or swallowing
- increased menstrual flow or vaginal bleeding
- prolonged bleeding from cuts
- red or black, tarry stools
- red or dark brown urine
- shortness of breath
- fast heartbeat
- hives or welts
- itching skin
- noisy breathing
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- redness of the skin
- skin rash
- tightness in the chest
- unusual tiredness or weakness
- Blue lips and fingernails
- blurred vision
- chest pain or discomfort
- coughing that sometimes produces a pink frothy sputum
- difficult, fast, or noisy breathing, sometimes with wheezing
- fast, irregular, pounding, or racing heartbeat or pulse
- inability to speak
- increased sweating
- low blood pressure or pulse
- numbness or tingling in the face, arms, or legs
- pale skin
- severe or sudden headache
- severe or sudden weakness in the arm or leg on one side of the body
- slurred speech
- swelling in the legs and ankles
- trouble with walking or speaking
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Urokinase is given as an injection through a needle placed into a vein. You will receive this injection in a clinic or hospital setting.
Urokinase is given slowly, usually over a period of 12 hours, using a continuous infusion pump.
Your breathing, blood pressure, oxygen levels, and other vital signs will be watched closely while you are receiving urokinase.
Since this medication is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.
Because you will receive urokinase in a clinical setting, you are not likely to miss a dose.
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Usual Adult Dose for Pulmonary Embolism
Initial dose: 4400 international units/kg IV at a rate of 90 mL/hr over 10 minutes
Maintenance dose: 4400 international units/kg/hr IV at a rate of 15 mL for 12 hours
-Institute treatment soon after onset of pulmonary embolism to avoid potential decrease in efficacy.
-Administration of this drug may be repeated as necessary.
-After infusing this drug, do not begin anticoagulation until activated partial thromboplastin time (aPTT) has decreased to less than twice the normal control value; if heparin is used, do not administer a loading dose of heparin; treatment should be followed by oral anticoagulants.
-Lysis of acute massive pulmonary emboli (obstruction of blood flow to a lobe or multiple segments).
-Lysis of pulmonary emboli accompanied by unstable hemodynamics (e.g., failure to maintain blood pressure without supportive measures).
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
Administration advice: The manufacturer product information should be consulted.
Storage requirements: Refrigerate powder at 2 to 8C (36 to 46F).
Reconstitution/preparation techniques: The manufacturer product information should be consulted.
IV compatibility: This drug should not be mixed with other medicinal products.
-Hematologic: Hematocrit, platelet count, and activated partial thromboplastin time (aPTT) should be obtained prior to starting treatment
-General: Vital signs should be observed frequently during and following infusion (blood pressure should not be taken in lower extremities to avoid dislodgement of possible deep vein thrombus)